|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||17.40 - 18.95|
|52 Week Range||17.40 - 18.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In the second quarter of 2018, Merck’s (MRK) Zetia generated revenues of $226.0 million compared to $367.0 million in the second quarter of 2017, reflecting a ~38% year-over-year (or YoY) decline and a ~26% sequential decline. In the second quarter of 2018, in the US and international markets (outside the US markets), Zetia generated revenues of $8.0 million and $218.0 million, respectively, compared to $122.0 million and $246.0 million in the second quarter of 2017.
Impax Asset Management Group plc (LON:IPX), a capital markets company based in United Kingdom, led the AIM gainers with a relatively large price hike in the past couple of weeks.Read More...
In this article I am going to calculate the intrinsic value of Impax Laboratories Inc (NASDAQ:IPXL) using the discounted cash flows (DCF) model. If you want to learn more aboutRead More...
Merck & Company’s (MRK) Zetia (ezetimibe) reported revenue of $305 million in Q1 2018 compared to $334 million in Q1 2017, a ~9% fall YoY (year-over-year) and a ~6% fall sequentially.
An administrative law judge at the Federal Trade Commission on Thursday dismissed the agency's antitrust complaint against generic drugmaker Impax Laboratories Inc. The agency had alleged that in June ...
Examining how Impax Laboratories Inc (NASDAQ:IPXL) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense checkRead More...
Impax Laboratories Inc (NASDAQ: IPXL) announced an agreement in October to merge with privately held Amneal Pharma, with 75 percent of the combined company held by Amneal shareholders and 25 percent by Impax Labs shareholders. Impax Labs' pending merger with Amneal is likely to result in "a generics market leader positioned to deliver attractive growth," Tsao said in a Tuesday note.
Generics drug companies Amneal Pharmaceuticals LLC and Impax Laboratories Inc have won U.S. antitrust approval to merge, the U.S. Federal Trade Commission said on Friday. Under the terms of the proposed settlement, the FTC said ANI Pharmaceuticals Inc will acquire seven products, Perrigo Company Plc will acquire Impax's rights to two products that it had partnered with Impax to manufacture and sell, and G&W Laboratories Inc will acquire Impax's marketing rights to one product that G&W manufactures for Impax. Adding to their woes, U.S. retail pharmacies, including Wal-Mart Stores Inc and Walgreens Boots Alliance Inc , are wielding more leverage when buying such drugs, leading to price erosion.
The U.S. Federal Trade Commission said on Friday it would require Impax Laboratories Inc and privately held Amneal Pharmaceuticals LLC to divest rights to 10 generic medications as a condition of their merger. The FTC said that under the terms of the proposed settlement ANI Pharmaceuticals Inc will acquire seven products, Perrigo Company Plc will acquire Impax's rights to two products that it had partnered with Impax to manufacture and sell, and G&W Laboratories Inc will acquire Impax's marketing rights to one product that G&W manufactures for Impax.
When Impax Asset Management Group plc’s (AIM:IPX) announced its latest earnings (30 September 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarksRead More...
Impax Laboratories (IPXL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Impax Laboratories Inc has agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn. According to the plaintiffs, Impax in 2008 settled a lawsuit it filed challenging a weak patent Medicis Pharmaceutical Corp held for Solodyn by agreeing to delay releasing its generic version until 2011. In exchange, Impax received $40 million, allowing Medicis to maintain its Solodyn monopoly longer, the plaintiffs allege.
Impax Laboratories Inc has reached a mid-trial settlement with retailers including CVS Health Corp and Rite Aid Corp who accused the drugmaker of entering into an anticompetitive deal to delay launching a generic, cheaper version of acne medication Solodyn. The deal, disclosed in papers filed in federal court in Boston on Sunday, resolved only part of the litigation now entering its third week of trial. Impax still faces claims by a class of consumers and insurers.
Solodyn has an indication for the treatment of inflammatory lesions of moderate to severe acne in patients 12 years and older. The generic version of Solodyn is the ninth generic tetracycline-class drug in Teva’s portfolio. According to IMS data, Solodyn Extended Release 65 mg and 115 mg tablets generated sales of ~$148 million in the United States in 2017.
Impax Laboratories Inc went to trial on Monday over allegations by major retailers and consumers that the company agreed to delay launching a generic version of acne medication Solodyn in exchange for millions of dollars from the manufacturer. The trial in Boston federal court is one of a handful to have taken place since the U.S. Supreme Court in 2013 said so-called "pay-for-delay" settlements resolving pharmaceutical patent lawsuits can violate antitrust laws. A lawyer for Impax, in his opening statement, denied there was any such arrangement to delay Solodyn's entry to the market.
Impax Laboratories Inc went to trial on Monday over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication's manufacturer. Jury selection began in Boston federal court in a case centered on an alleged "pay-for-delay" settlement, in which a generic manufacturer agrees to resolve legal challenges to a brand-name drug's patents and delay making a cheaper version. The trial is one of a handful to have taken place since the U.S. Supreme Court in 2013 said that such settlements, which also involve brand-name drug companies paying the generic manufacturers, can be found to be anticompetitive.
Impax Laboratories Inc has agreed to pay $35 million to resolve part of litigation over claims it entered into an anticompetitive deal in a patent case to delay releasing a generic version of the acne medication Solodyn. The settlement was disclosed in papers filed in federal court in Boston on Saturday. It resolved part of the antitrust litigation Impax faces over Solodyn related to sales of the drug to direct purchasers such as retailers and wholesalers.
Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.
Moody's Investors Service, ("Moody's") rated Amneal Pharmaceuticals, LLC's ("Amneal") proposed $2.7 billion senior secured term loan B1. Moody's also affirmed Amneal's current ratings ...
Impax (IPXL) reports dismal fourth-quarter results with earnings and sales coming in lower than the year-ago period as well as the estimates.